What is ABECMA? ABECMA (idecabtagene vicleucel) is a prescription medicine for the treatment of multiple myeloma in patients who have received at least three kinds of treatment regimens that have not worked or have stopped working. ABECMA is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your multiple myeloma cells.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
In a clinical study of 30.9 months follow-up (median), people treated with ABECMA lived longer without the disease getting worse or passing away, 13.8 months vs 4.4 months with standard treatments.
*Median is the middle number in a group of numbers arranged from lowest to highest.
CAR=chimeric antigen receptor.
Your T cells will be collected through a process called apheresis
(sometimes called leukapheresis).
Time: 2-6 hours
Location: Certified treatment or apheresis center
After your T cells are collected, they are sent to a specialized manufacturing laboratory.
Time: About 4 weeks (time may vary)
Location: Specialized manufacturing laboratory
There is a risk that the manufacturing process may not work. In an ABECMA clinical study, 6 out of 249 people were impacted.
Talk with your doctor for more information.
Time: 3 days of short-course chemotherapy
Location: Treatment is given at the center by appointment
You will receive your one-time ABECMA infusion at a certified treatment center from your trained healthcare team.
Time: Up to 30 minutes per infusion bag (1 or more)
Location: Certified treatment center (Day 1 of 1-week hospital stay)
*The treatment process includes blood collection, CAR T cell creation, administration, and adverse event monitoring.
In the weeks following your ABECMA infusion, you will be monitored for side effects.
For the first 7 days after treatment
Monitoring at the treatment center
During weeks 2 to 4
After at least 4 weeks of monitoring
Monitor for side effects and tell your doctor right away if you feel symptoms of cytokine release syndrome or neurologic toxicity
You will not require any additional treatment† while
responding to your one-time infusion‡ of ABECMA
†Regular check-ins with your healthcare team are still needed.
‡The treatment process includes blood collection, CAR T cell creation, administration, and adverse event monitoring.
CAR=chimeric antigen receptor.